Physician profile
David Furman
NPI 1831548510
$4,037.06
in general payments reported to CMS, 2019-2025
35 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $701 · 2021: $1,450 · 2022: $816 · 2023: $457 · 2024: $30.88 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.50 | 2019-2022 | |
| Abbvie INC. | $599.38 | 2021-2023 | |
| Novo Nordisk INC | $415.94 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $352.63 | 2019-2023 | |
| Glaxosmithkline, LLC. | $261.66 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $236.77 | 2019-2024 | |
| Lilly USA, LLC | $221.58 | 2020-2023 | Emgality, Jardiance, Mounjaro |
| Stryker Corporation | $145.17 | 2019 | |
| Merck Sharp & Dohme LLC | $131.16 | 2020-2023 | Steglatro, Belsomra, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.07 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.84 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $103.56 | 2020-2023 | Trintellix |
| Amgen INC. | $84.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.41 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $50.86 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $50.59 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $49.35 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.25 | 2022 | |
| Eisai INC. | $45.72 | 2021-2022 | |
| Corium, LLC | $36.37 | 2022-2023 | Azstarys |
| Genentech USA, INC. | $34.17 | 2019-2022 | |
| Amarin Pharma, INC. | $30.75 | 2020-2021 | |
| Abbott Laboratories | $29.49 | 2021 | |
| Antares Pharma, INC. | $26.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.72 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.29 | 2021 | |
| Astellas Pharma US INC | $19.84 | 2021 | |
| Allergan, INC. | $17.63 | 2020 | |
| Almatica Pharma LLC | $15.82 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.81 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $13.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.02 | 2022 | |
| Dexcom, INC. | $11.68 | 2021 | |
| Acadia Pharmaceuticals INC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.